355 related articles for article (PubMed ID: 20636021)
1. Safety analysis of ex vivo-expanded NK and NK-like T cells administered to cancer patients: a phase I clinical study.
Barkholt L; Alici E; Conrad R; Sutlu T; Gilljam M; Stellan B; Christensson B; Guven H; Björkström NK; Söderdahl G; Cederlund K; Kimby E; Aschan J; Ringdén O; Ljunggren HG; Dilber MS
Immunotherapy; 2009 Sep; 1(5):753-64. PubMed ID: 20636021
[TBL] [Abstract][Full Text] [Related]
2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
3. Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation.
Passweg JR; Tichelli A; Meyer-Monard S; Heim D; Stern M; Kühne T; Favre G; Gratwohl A
Leukemia; 2004 Nov; 18(11):1835-8. PubMed ID: 15457184
[TBL] [Abstract][Full Text] [Related]
4. Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy.
Ayello J; van de Ven C; Cairo E; Hochberg J; Baxi L; Satwani P; Cairo MS
Exp Hematol; 2009 Oct; 37(10):1216-29. PubMed ID: 19638292
[TBL] [Abstract][Full Text] [Related]
5. Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation.
Chen G; Wu D; Wang Y; Cen J; Feng Y; Sun A; Tang X; Chang H; Zhu Z
Eur J Haematol; 2008 Sep; 81(3):226-35. PubMed ID: 18573173
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of ex vivo expanded human NK cells on antileukemia activity in SCID-beige mice.
Guimarães F; Guven H; Donati D; Christensson B; Ljunggren HG; Bejarano MT; Dilber MS
Leukemia; 2006 May; 20(5):833-9. PubMed ID: 16511516
[TBL] [Abstract][Full Text] [Related]
7. Pre-emptive immunotherapy with purified natural killer cells after haploidentical SCT: a prospective phase II study in two centers.
Stern M; Passweg JR; Meyer-Monard S; Esser R; Tonn T; Soerensen J; Paulussen M; Gratwohl A; Klingebiel T; Bader P; Tichelli A; Schwabe D; Koehl U
Bone Marrow Transplant; 2013 Mar; 48(3):433-8. PubMed ID: 22941380
[TBL] [Abstract][Full Text] [Related]
8. At the Bedside: Innate immunity as an immunotherapy tool for hematological malignancies.
Locatelli F; Merli P; Rutella S
J Leukoc Biol; 2013 Dec; 94(6):1141-57. PubMed ID: 24096380
[TBL] [Abstract][Full Text] [Related]
9. Clinical-scale isolation of interleukin-2-stimulated liver natural killer cells for treatment of liver transplantation with hepatocellular carcinoma.
Ohira M; Nishida S; Tryphonopoulos P; Tekin A; Selvaggi G; Moon J; Levi D; Ricordi C; Ishiyama K; Tanaka Y; Ohdan H; Tzakis AG
Cell Transplant; 2012; 21(7):1397-406. PubMed ID: 22469170
[TBL] [Abstract][Full Text] [Related]
10. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.
Asai O; Longo DL; Tian ZG; Hornung RL; Taub DD; Ruscetti FW; Murphy WJ
J Clin Invest; 1998 May; 101(9):1835-42. PubMed ID: 9576746
[TBL] [Abstract][Full Text] [Related]
11. Generation of donor natural killer cells from CD34(+) progenitor cells and subsequent infusion after HLA-mismatched allogeneic hematopoietic cell transplantation: a feasibility study.
Yoon SR; Lee YS; Yang SH; Ahn KH; Lee JH; Lee JH; Kim DY; Kang YA; Jeon M; Seol M; Ryu SG; Chung JW; Choi I; Lee KH
Bone Marrow Transplant; 2010 Jun; 45(6):1038-46. PubMed ID: 19881555
[TBL] [Abstract][Full Text] [Related]
12. Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity.
Miller JS; Tessmer-Tuck J; Pierson BA; Weisdorf D; McGlave P; Blazar BR; Katsanis E; Verfaillie C; Lebkowski J; Radford J; Burns LJ
Biol Blood Marrow Transplant; 1997 Apr; 3(1):34-44. PubMed ID: 9209739
[TBL] [Abstract][Full Text] [Related]
13. IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial.
Burns LJ; Weisdorf DJ; DeFor TE; Vesole DH; Repka TL; Blazar BR; Burger SR; Panoskaltsis-Mortari A; Keever-Taylor CA; Zhang MJ; Miller JS
Bone Marrow Transplant; 2003 Jul; 32(2):177-86. PubMed ID: 12838283
[TBL] [Abstract][Full Text] [Related]
14. Use of natural killer cells in hematopoetic stem cell transplantation.
Passweg JR; Stern M; Koehl U; Uharek L; Tichelli A
Bone Marrow Transplant; 2005 Apr; 35(7):637-43. PubMed ID: 15654351
[TBL] [Abstract][Full Text] [Related]
15. Adoptive therapy by transfusing expanded donor murine natural killer T cells can suppress acute graft-versus-host disease in allogeneic bone marrow transplantation.
Yang J; Gao L; Liu Y; Ren Y; Xie R; Fan H; Qian K
Transfusion; 2010 Feb; 50(2):407-17. PubMed ID: 19788510
[TBL] [Abstract][Full Text] [Related]
16. Analysis of donor NK and T cells infused in patients undergoing MHC-matched allogeneic hematopoietic transplantation.
Pascal V; Brunet C; Pradel V; Thirion X; Andre P; Faucher C; Sampol J; Dignat-George F; Blaise D; Vivier E; Chabannon C
Leukemia; 2002 Nov; 16(11):2259-66. PubMed ID: 12399971
[TBL] [Abstract][Full Text] [Related]
17. NK cell alloreactivity and allogeneic hematopoietic stem cell transplantation.
Ruggeri L; Mancusi A; Burchielli E; Capanni M; Carotti A; Aloisi T; Aversa F; Martelli MF; Velardi A
Blood Cells Mol Dis; 2008; 40(1):84-90. PubMed ID: 17964828
[TBL] [Abstract][Full Text] [Related]
18. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.
Posthuma EF; Marijt EW; Barge RM; van Soest RA; Baas IO; Starrenburg CW; van Zelderen-Bhola SL; Fibbe WE; Smit WM; Willemze R; Falkenburg JH
Biol Blood Marrow Transplant; 2004 Mar; 10(3):204-12. PubMed ID: 14993886
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of donor lymphocyte infusions following mismatched stem cell transplantation.
Or R; Hadar E; Bitan M; Resnick IB; Aker M; Ackerstein A; Samuel S; Tsirigotis P; Gesundheit B; Slavin S; Shapira MY
Biol Blood Marrow Transplant; 2006 Dec; 12(12):1295-301. PubMed ID: 17162211
[TBL] [Abstract][Full Text] [Related]
20. Tracking ex vivo-expanded CD4+CD25+ and CD8+CD25+ regulatory T cells after infusion to prevent donor lymphocyte infusion-induced lethal acute graft-versus-host disease.
Xia G; Kovochich M; Truitt RL; Johnson BD
Biol Blood Marrow Transplant; 2004 Nov; 10(11):748-60. PubMed ID: 15505606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
